Founded in 2002 as a spin-out of the Bacterial Microarray Group at St George's, University of London, BUGS Bioscience specializes in pathogen genomics and is a leading supplier of high-quality molecular surveillance solutions and services. They have developed a proprietary technology platform that integrates high throughput molecular approaches with advanced algorithms and software to gain new insights into the genomic composition of bacteria and viruses in complex clinical samples. Their London-based service laboratory provides advanced molecular surveillance services to pharmaceutical companies and NGOs involved in vaccine development and roll-out, helping improve understanding of vaccine impact on pathogen carriage and associated disease. What sets BUGS Bioscience apart is their commitment to a collaborative, not-for-profit business model, with revenues reinvested in further developing their integrated technology and software platform to support organizations fighting infectious diseases, particularly in children, through universal vaccination. They maintain close links with leading academic groups in the field, both in terms of technology contribution and improving global molecular surveillance of infectious diseases.